These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 21194571)

  • 1. Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction slowing from nonclinical models to clinical.
    Heath BM; Cui Y; Worton S; Lawton B; Ward G; Ballini E; Doe CP; Ellis C; Patel BA; McMahon NC
    J Pharmacol Toxicol Methods; 2011; 63(3):258-68. PubMed ID: 21194571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detecting drug-induced prolongation of the QRS complex: new insights for cardiac safety assessment.
    Cros C; Skinner M; Moors J; Lainee P; Valentin JP
    Toxicol Appl Pharmacol; 2012 Dec; 265(2):200-8. PubMed ID: 23073507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modeling of QRS-prolongation by flecainide: heart rate-dependent effects during sinus rhythm in conscious telemetered dogs.
    Sällström J; Al-Saffar A; Pehrson R
    J Pharmacol Toxicol Methods; 2014; 69(1):24-9. PubMed ID: 24140388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome.
    Shimizu W; Antzelevitch C; Suyama K; Kurita T; Taguchi A; Aihara N; Takaki H; Sunagawa K; Kamakura S
    J Cardiovasc Electrophysiol; 2000 Dec; 11(12):1320-9. PubMed ID: 11196553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms underlying increased right ventricular conduction sensitivity to flecainide challenge.
    Veeraraghavan R; Poelzing S
    Cardiovasc Res; 2008 Mar; 77(4):749-56. PubMed ID: 18056761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing use-dependent inhibition of the cardiac Na(+/-) current (I(Na)) in the PatchXpress automated patch clamp.
    Penniman JR; Kim DC; Salata JJ; Imredy JP
    J Pharmacol Toxicol Methods; 2010; 62(2):107-18. PubMed ID: 20601018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization.
    Osadchii OE
    J Cardiovasc Pharmacol; 2014 Mar; 63(3):240-51. PubMed ID: 24220314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An examination of the cardiac actions of PD117,302, a κ-opioid receptor agonist.
    Pugsley MK; Saint DA; Hayes ES; Abraham S; Walker MJ
    Eur J Pharmacol; 2015 Aug; 761():330-40. PubMed ID: 26086860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrocardiographic interactions between pinacidil, a potassium channel opener and class I antiarrhythmic agents in guinea-pig isolated perfused heart.
    Yang Q; Padrini R; Bova S; Piovan D; Magnolfi G
    Br J Pharmacol; 1995 Apr; 114(8):1745-9. PubMed ID: 7599944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block.
    Desaphy JF; De Luca A; Didonna MP; George AL; Camerino Conte D
    J Physiol; 2004 Jan; 554(Pt 2):321-34. PubMed ID: 14608015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide.
    Desaphy JF; Dipalma A; Costanza T; Bruno C; Lentini G; Franchini C; George A; Conte Camerino D
    Br J Pharmacol; 2010 Jul; 160(6):1521-33. PubMed ID: 20590641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications.
    Ingleby-Talecki L; van Dijkman SC; Oosterholt SP; Della Pasqua O; Winter C; Cunnington M; Rebar L; Forero-Schwanhaeuser S; Patel V; Cooper JA; Bahinski A; Chaudhary KW
    Clin Transl Sci; 2022 Aug; 15(8):1978-1989. PubMed ID: 35579204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.
    Lu HR; Rohrbacher J; Vlaminckx E; Van Ammel K; Yan GX; Gallacher DJ
    Br J Pharmacol; 2010 May; 160(1):60-76. PubMed ID: 20331615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class Ic antiarrhythmics block human skeletal muscle Na channel during myotonia-like stimulation.
    Aoike F; Takahashi MP; Sakoda S
    Eur J Pharmacol; 2006 Feb; 532(1-2):24-31. PubMed ID: 16473348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks.
    Harmer AR; Abi-Gerges N; Easter A; Woods A; Lawrence CL; Small BG; Valentin JP; Pollard CE
    J Pharmacol Toxicol Methods; 2008; 57(1):30-41. PubMed ID: 17980627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological activation of IKr impairs conduction in guinea pig hearts.
    Larsen AP; Olesen SP; Grunnet M; Poelzing S
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):923-9. PubMed ID: 20163495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
    Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
    J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade.
    Ranger S; Talajic M; Lemery R; Roy D; Nattel S
    Circulation; 1989 May; 79(5):1000-6. PubMed ID: 2540920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
    Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC
    J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined application of class I antiarrhythmic drugs causes "additive", "reductive", or "synergistic" sodium channel block in cardiac muscles.
    Kawamura T; Kodama I; Toyama J; Hayashi H; Saito H; Yamada K
    Cardiovasc Res; 1990 Nov; 24(11):925-31. PubMed ID: 2176934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.